Biotech Values

[dewophile]

I totally agree ENTA is undervalued. The bear case is that HCV royalties are on the decline, there are some promising RSV vaccine candidates (GSK talks about it regularly now for example), HBV is crowded, and their first stab at NASH seems like a flop
My bull take:
1. HCV cases are on the rise and still have a healthy run rate
2. RSV vaccines are a very long way out with a poor track record and there are bound to be many cases still even in a post vaccine world. Also testing for viruses (RSV included) is going to ramp up in a post covid world
3. ENTA has as good a chance as anyone in HBV
4. The follow on NASH drug may have legs
5. You would think a successful antiviral company in the midst of a pandemic might have some added appeal overall (not just interest from pharma but also public funding, etc.)